2019 Fiscal Year Final Research Report
The predictors of infusion related reaction by rituximab
| Project/Area Number |
19K21224
|
|---|
| Project/Area Number (Other) |
18H06104 (2018)
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund (2019)
Single-year Grants (2018) |
|---|
| Review Section |
0801:Pharmaceutical sciences and related fields
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-08-24 – 2020-03-31
|
| Keywords | インフュージョンリアクション / リツキシマブ / レトロスペクティブ / 抗体医薬品 |
|---|
| Outline of Final Research Achievements |
We investigated the frequency of infusion related reaction (IRR), a characteristic acute toxicity of rituximab, in the Department of Hematology and Oncology of Osaka University Hospital. The frequency of IRR at the first administration was 47.0%, of which 64.2% required the discontinuation of rituximab administration or the additional medication for IRR. And, the sex which is the patient information and the lymphocyte count which is the laboratory value were significantly associated with IRR. Although there was no statistically significant difference, the frequency of IRR tended to differ depending on the tumor type.
|
| Free Research Field |
医療薬学
|
| Academic Significance and Societal Importance of the Research Achievements |
リツキシマブによる特徴的な急性期毒性であるインフュージョンリアクション (IRR) は発現頻度が高く、死亡に至った例も報告されている。投与中または投与後に高頻度で発現するIRRは、その副作用を被る患者はもちろんのこと、IRRの発現に備えなければならない医療従事者の負担も大きなものとなっている。本研究成果は、IRRの発現に関連する因子の一端を明らかにしており、IRRの発現を回避・軽減する手法の開発に貢献し、実臨床的な課題克服につながることが期待される。
|
